XML 113 R43.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2025
USD ($)
segment
Sep. 30, 2024
USD ($)
segment
Segment Reporting Information [Line Items]                
Number of operating segments | segment             1 1
Number of reportable segments | segment             1 1
Revenues $ 12,807     $ 13,542     $ 31,530 $ 45,694
Costs and expenses:                
Total Manufacture and Supply Expenses 4,506     4,437     12,719 13,352
Total Research and Development Expenses 4,530     5,269     13,996 15,363
General & Administrative expenses:                
Total Selling, General and Administrative Expenses 15,250     12,126     47,027 34,171
Total costs and expenses 24,286     21,832     73,742 62,886
Loss from operations (11,479)     (8,290)     (42,212) (17,192)
Net loss before income taxes (15,446)     (11,509)     (51,924) (27,082)
Net loss (15,446) $ (13,548) $ (22,930) (11,509) $ (2,745) $ (12,828) (51,924) (27,082)
Comprehensive loss (15,446)     (11,509)     (51,924) (27,082)
Reportable Segment                
Segment Reporting Information [Line Items]                
Revenues 12,807     13,542     31,530 45,694
Costs and expenses:                
Total Manufacture and Supply Expenses 4,506     4,437     12,719 13,352
Total Research and Development Expenses 4,530     5,269     13,996 15,363
Selling expenses:                
Total Selling expenses 3,915     1,967     10,391 4,108
General & Administrative expenses:                
Total General and Administrative Expenses 11,335     10,159     36,636 30,063
Total Selling, General and Administrative Expenses 15,250     12,126     47,027 34,171
Total costs and expenses 24,286     21,832     73,742 62,886
Loss from operations (11,479)     (8,290)     (42,212) (17,192)
Other income/(expenses), net (3,967)     (3,219)     (9,712) (9,890)
Net loss before income taxes (15,446)     (11,509)     (51,924) (27,082)
Net loss (15,446)     (11,509)     (51,924) (27,082)
Comprehensive loss (15,446)     (11,509)     (51,924) (27,082)
Reportable Segment | Anaphylm project expenses                
Costs and expenses:                
Total Research and Development Expenses 912     2,601     4,604 7,448
Reportable Segment | AQST-108 project expenses                
Costs and expenses:                
Total Research and Development Expenses (131)     (5)     254 784
Reportable Segment | Libervant project expenses                
Costs and expenses:                
Total Research and Development Expenses 0     (19)     0 (2)
Reportable Segment | Personnel costs                
Costs and expenses:                
Total Research and Development Expenses 3,001     1,884     7,351 5,627
Selling expenses:                
Total Selling expenses 805     598     2,108 1,784
General & Administrative expenses:                
Total General and Administrative Expenses 5,017     4,906     15,025 14,485
Reportable Segment | Other                
Costs and expenses:                
Total Research and Development Expenses 748     808     1,787 1,506
Selling expenses:                
Total Selling expenses 3,110     1,369     8,283 2,324
General & Administrative expenses:                
Total General and Administrative Expenses $ 6,318     $ 5,253     $ 21,611 $ 15,578